[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100478848":3},{"organization":4,"outcomesModule":7,"designInfo":23,"detailedDescription":22,"studyPopulation":22,"armGroups":29,"interventions":38,"overallOfficials":22,"centralContacts":57,"locations":64,"responsibleParty":82,"collaborators":22,"id":84,"slug":22,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":22,"eligibilityCriteria":88,"healthyVolunteers":85,"sex":89,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":22,"studyType":95,"phases":96,"briefSummary":98,"conditions":99,"keywords":22,"overallStatus":67,"whyStopped":22,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Fuzhou General Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":22},[9],{"measure":10,"description":11,"timeFrame":12},"progression free survival","Time from enrollment to the onset of disease progression or death","up to 24 months",[14,18],{"measure":15,"description":16,"timeFrame":17},"Objective Response Rate (ORR)","Objective Response Rate Determine the tumor shrinkage rate, tumor boundary and the adhesion of tumor","every 6 weeks （up to 24 months）",{"measure":19,"description":20,"timeFrame":21},"Overall survival (OS)","Defined from date of Signing ICF to date of first documentation of death from any cause or censored at the date of the last follow-up.","every 3 months (up to 24 months)",null,{"allocation":24,"interventionModel":25,"interventionModelDescription":22,"primaryPurpose":26,"observationalModel":22,"timePerspective":22,"maskingInfo":27},"NA","SINGLE_GROUP","TREATMENT",{"masking":28,"maskingDescription":22,"whoMasked":22},"NONE",[30],{"label":31,"type":32,"description":22,"interventionNames":33},"Tislelizumab combined with chemothapy","EXPERIMENTAL",[34,35,36,37],"Drug: Tislelizumab","Drug: Albumin paclitaxel","Drug: Nedaplatin","Radiation: radiotherapy",[39,44,48,52],{"type":40,"name":41,"description":42,"armGroupLabels":43,"otherNames":22},"DRUG","Tislelizumab","Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks",[31],{"type":40,"name":45,"description":46,"armGroupLabels":47,"otherNames":22},"Albumin paclitaxel","Participants will receive Albumin paclitaxel 260 mg\u002Fm2 , day 1 of every 3 weeks",[31],{"type":40,"name":49,"description":50,"armGroupLabels":51,"otherNames":22},"Nedaplatin","Participants will receive Nedaplatin 80 mg\u002Fm2 , day 1 of every 3 weeks",[31],{"type":53,"name":54,"description":55,"armGroupLabels":56,"otherNames":22},"RADIATION","radiotherapy","50-60Gy\u002F25-30f",[31],[58],{"name":59,"role":60,"phone":61,"phoneExt":62,"email":63},"Fu zhi chao, Doctor of Medicine","CONTACT","13774562945","86","fauster1112@126.com",[65],{"facility":66,"status":67,"city":68,"state":69,"zip":70,"country":71,"countryCode":72,"cosmosGeoPoint":73,"geoPoint":78,"contacts":79},"Ye zai sheng","RECRUITING","Fuzhou","Fujian","350500","China","CN",{"type":74,"coordinates":75},"Point",[76,77],119.30611,26.06139,{"lat":77,"lon":76},[80],{"name":81,"role":60,"phone":61,"phoneExt":62,"email":63},"Fu zhi chao, doctor",{"type":83,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100478848",false,"NCT05515315","Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n* Histologically confirmed localized ESCC that is suitable for cCRT, including: stage II-IVA (AJCC version 8) inoperable ESCC (medically unfit for surgery or refusing surgical intervention);;\n* Aged 18-70, both sexes;\n* ECOG score 0-1\n* The presence of measurable and\u002For nonmeasurable lesions that met the definition of RECIST1.1;\n* Adequate organ and bone marrow function, meeting the following definitions:\n\n  1. Blood routine (no blood transfusion, no granulocyte colony-stimulating factor \\[G-CSF\\], and no other drugs were used within 14 days before treatment);Absolute neutrophil count (ANC) ≥1.5×109\u002FL;Hemoglobin (HB) ≥9.0 g\u002FdL;Platelet count (PLT) ≥100×109\u002FL;\n  2. Blood biochemistry Creatinine clearance rate ≥60 mL\u002Fmin;Total bilirubin (TBIL) ≤ 1.5×ULN;Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level ≤2.5×ULN;\n* Expected survival time \\> 6 months;\n* Fertile female subjects and male subjects with partners of reproductive age are required to use a medically approved contraceptive method during the study treatment period and for at least 3 months after the last treatment;\n* Patients who volunteered to participate in this study and signed the informed consent form.\n\nExclusion Criteria:\n\n* A history of fistula caused by primary tumor invasion;\n* Presence of clinically uncontrolled pleural effusion, pericardial effusion, or ascites that required repeated drainage or medical intervention (within 2 weeks before randomization);\n* Known intolerance or resistance to chemotherapy specified in the trial protocol;\n* have received any other ESCC antitumor therapy (e.g., therapy targeting PD-1, PD-L1, PD-L2 or other tumor immunotherapy, radiotherapy, targeted therapy, ablation or other systemic or local antitumor therapy);\n* Patients with active autoimmune disease or a history of autoimmune disease that may relapse, or a known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;\n* History of interstitial lung disease, non-infectious pneumonia or uncontrolled systemic diseases, including pulmonary fibrosis and acute lung disease;\n* Severe chronic or active infection (including tuberculosis infection) requiring systemic antimicrobial therapy, antifungal therapy or antiviral therapy before enrollment;\n* Known history of HIV infection;\n* Other malignancies (except cured basal cell carcinoma of the skin, carcinoma in situ of the breast and carcinoma in situ of the cervix) in the past 5 years;\n* Received live vaccine within 28 days before enrollment;\n* while participating in another therapeutic clinical trial.","ALL","18 Years","70 Years",{"count":93,"type":94},93,"ESTIMATED","INTERVENTIONAL",[97],"PHASE2","To explore the efficacy of Tislelizumab combined with chemotherapy in the treatment of locally unresectable esophageal squamous cell carcinoma (ESCC)",[100],"Immunotherapy Esophagus Cancer","2024-02-04",{"date":103,"type":104},"2024-02-07","ACTUAL",{"date":106,"type":104},"2022-05-31",{"date":108,"type":94},"2027-05-31",{"name":5,"class":6},1]